Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.

Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornbleet, M. A., McElwain, T. J., Kumar, P. J., Filshie, J., Selby, P., Carter, R. L., Hedley, D. W., Clark, M. L., Millar, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011461/
https://www.ncbi.nlm.nih.gov/pubmed/6351883
_version_ 1782136534491725824
author Cornbleet, M. A.
McElwain, T. J.
Kumar, P. J.
Filshie, J.
Selby, P.
Carter, R. L.
Hedley, D. W.
Clark, M. L.
Millar, J. L.
author_facet Cornbleet, M. A.
McElwain, T. J.
Kumar, P. J.
Filshie, J.
Selby, P.
Carter, R. L.
Hedley, D. W.
Clark, M. L.
Millar, J. L.
author_sort Cornbleet, M. A.
collection PubMed
description Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of tumour response to treatment and in 2 patients complete remissions were observed. However in most patients, responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months from first recorded evidence of distant metastatic disease.
format Text
id pubmed-2011461
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20114612009-09-10 Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Cornbleet, M. A. McElwain, T. J. Kumar, P. J. Filshie, J. Selby, P. Carter, R. L. Hedley, D. W. Clark, M. L. Millar, J. L. Br J Cancer Research Article Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of tumour response to treatment and in 2 patients complete remissions were observed. However in most patients, responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months from first recorded evidence of distant metastatic disease. Nature Publishing Group 1983-09 /pmc/articles/PMC2011461/ /pubmed/6351883 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Cornbleet, M. A.
McElwain, T. J.
Kumar, P. J.
Filshie, J.
Selby, P.
Carter, R. L.
Hedley, D. W.
Clark, M. L.
Millar, J. L.
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title_full Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title_fullStr Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title_full_unstemmed Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title_short Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
title_sort treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011461/
https://www.ncbi.nlm.nih.gov/pubmed/6351883
work_keys_str_mv AT cornbleetma treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT mcelwaintj treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT kumarpj treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT filshiej treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT selbyp treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT carterrl treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT hedleydw treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT clarkml treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation
AT millarjl treatmentofadvancedmalignantmelanomawithhighdosemelphalanandautologousbonemarrowtransplantation

Ejemplares similares